Bristol Myers’ prized schizophrenia drug stumbles in testing

A late-stage study found Cobenfy wasn’t better than a placebo as an add-on to atypical antipsychotics. Some analysts view the failure as a “significant hit” to the drug’s commercial outlook.

Roche, answering tariff threat, pledges $50B to US drug production

The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing facilities in the U.S. 

Inside the market of emerging biotech

Sanofi, Regeneron win FDA nod for Dupixent in chronic hives

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales potential compared to other emerging medicines for the condition.

Arkansas passes law banning PBMs from owning pharmacies

The law in particular will affect CVS and UnitedHealth, both of which operate physical pharmacies in the state along with specialty and mail-order pharmacy businesses.

CDC panel backs broader use of RSV shots

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending booster shots.

GSK prepares to relaunch Blenrep; Activists challenge another ‘zombie’ biotech

U.K. regulators cleared a multiple myeloma drug GSK withdrew from market three years ago. Elsewhere, an investment firm pressed Elevation Oncology to liquidate and the FDA relaxed risk monitoring requirements for Camzyos.

Cheaper Chinese HPV Vaccines Turn Merck’s Gardasil From Boom to Bust